Literature DB >> 14769729

Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging.

Bernard Duysinx1, Delphine Nguyen, Renaud Louis, Didier Cataldo, Tarik Belhocine, Pierre Bartsch, Thierry Bury.   

Abstract

STUDY
OBJECTIVES: To study the ability of positron emission tomography (PET) using 18-fluorodeoxyglucose (FDG) to distinguish between benign and malignant disease in exudative pleural effusions and pleural thickening.
DESIGN: Prospective study of 98 consecutive patients presenting with either pleural thickening or an exudative pleural effusion.
SETTING: Department of pulmonary medicine of a university hospital.
METHODS: FDG-PET was performed on each subject before invasive procedures were used to determine the etiologic diagnosis. FDG-PET data were analyzed by visual interpretation.
RESULTS: Sixty-three of 98 patients were found to have malignant pleural disease after histologic analysis. Sixty-one of 63 patients with histologically confirmed malignant disease showed FDG uptake within the area of pleural thickening. Uptake was graded as intense in 51 cases and moderate in 10 cases. Only two patients with malignant pleural disease did not show increased FDG uptake. FDG-PET imaging showed an absence of FDG uptake, and correctly classified 31 of 35 benign lesions. For the remaining four lesions, intense FDG uptake was seen in one case of parapneumonic effusion, while moderate and localized uptake was observed in one parapneumonic, one tuberculous, and one uremic pleurisy. The sensitivity of the method to identify malignancy was 96.8% with a negative predictive value of 93.9%, while its specificity was 88.5% and its positive predictive value was 93.8%.
CONCLUSIONS: Our results suggest that FDG-PET is an effective tool for differentiating between benign and malignant pleural diseases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769729     DOI: 10.1378/chest.125.2.489

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  22 in total

1.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

2.  Diagnostic value of neurotrophin expression in malignant pleural effusions.

Authors:  Bernard C Duysinx; Astrid Paulus; Vincent Heinen; Delphine Nguyen; Monique Henket; Jean-Louis Corhay; Renaud Louis
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

3.  Mesothelioma - Update on Diagnostic Strategies.

Authors:  Carmen M Rosario; Xiaoqi Lin; David W Kamp
Journal:  Clin Pulm Med       Date:  2012-11

4.  Unusual Contiguous Soft Tissue Spread of Advanced Malignant Mesothelioma Detected by FDG PET/CT.

Authors:  Yuyang Zhang; Jamie Edwards; Hadyn Williams; Zhonglin Hao; Samir Khleif; Darko Pucar
Journal:  Nucl Med Mol Imaging       Date:  2016-06-06

5.  Preliminary study of positron emission tomography/computed tomography and plasma osteopontin levels in patients with asbestos-related pleural disease.

Authors:  Seiji Kurata; Masatoshi Ishibashi; Koichi Azuma; Hayato Kaida; Shinzo Takamori; Kiminori Fujimoto; Maiko Kobayashi; Yasumitsu Hirose; Hisamichi Aizawa; Naofumi Hayabuchi
Journal:  Jpn J Radiol       Date:  2010-07-27       Impact factor: 2.374

Review 6.  Video assisted thoracoscopic and open chest surgery in diagnosis and treatment of malignant pleural diseases.

Authors:  Periklis Perikleous; David A Waller
Journal:  J Vis Surg       Date:  2017-06-22

Review 7.  Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma.

Authors:  Kazuhiro Kitajima; Hiroshi Doi; Kozo Kuribayashi
Journal:  Jpn J Radiol       Date:  2016-05-24       Impact factor: 2.374

8.  Current perspective on the diagnosis of malignant pleural effusion.

Authors:  Jun Hyeok Lim; Jeong-Seon Ryu
Journal:  J Thorac Dis       Date:  2019-05       Impact factor: 2.895

9.  Asymptomatic primary tuberculous pleurisy with intense 18-fluorodeoxyglucose uptake mimicking malignant mesothelioma.

Authors:  Tsutomu Shinohara; Naoki Shiota; Motohiko Kume; Norihiko Hamada; Keishi Naruse; Fumitaka Ogushi
Journal:  BMC Infect Dis       Date:  2013-01-14       Impact factor: 3.090

Review 10.  Malignant mesothelioma.

Authors:  Alastair J Moore; Robert J Parker; John Wiggins
Journal:  Orphanet J Rare Dis       Date:  2008-12-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.